[HTML][HTML] Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients
T Lorant, M Bengtsson, T Eich, BM Eriksson… - American Journal of …, 2018 - Elsevier
Safety, immunogenicity, pharmacokinetics, and efficacy of the IgG-degrading enzyme of
Streptococcus pyogenes (IdeS [imlifidase]) were assessed in a single-center, open-label
ascending-dose study in highly sensitized patients with chronic kidney disease. Eight
patients with cytotoxic PRAs (median cytotoxic PRAs of 64%) at enrollment received 1 or 2
intravenous infusions of IdeS on consecutive days (0.12 mg/kg body weight× 2 [n= 3]; 0.25
mg/kg× 1 [n= 3], or 0.25 mg/kg× 2 [n= 2]). IgG degradation was observed in all subjects after …
Streptococcus pyogenes (IdeS [imlifidase]) were assessed in a single-center, open-label
ascending-dose study in highly sensitized patients with chronic kidney disease. Eight
patients with cytotoxic PRAs (median cytotoxic PRAs of 64%) at enrollment received 1 or 2
intravenous infusions of IdeS on consecutive days (0.12 mg/kg body weight× 2 [n= 3]; 0.25
mg/kg× 1 [n= 3], or 0.25 mg/kg× 2 [n= 2]). IgG degradation was observed in all subjects after …